AgomAb Therapeutics (Ticker: AGMB US) is a Belgium-based clinical-stage biotechnology company specializing in the development of fibrosis treatments for immunology and inflammatory diseases. The company plans to list on the NASDAQ on February 6, 2026. AgomAb intends to offer 12.5 million American Depositary Shares (ADS) at a price range of $15.00 to $17.00 per share. At the midpoint of this range, the IPO would raise $200 million, resulting in a market capitalization of approximately $779.8 million.

The company’s mission focuses on resolving fibrosis and restoring organ function by targeting specific signaling pathways, such as the TGFβ pathway. Its lead product candidate, Ontunisertib (AGMB-129), is an oral treatment being developed for Crohn’s disease with fibrostenosis. Additionally, AgomAb is developing AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF). Reportedly, the company plans to use the IPO proceeds to fund the continued clinical development of these candidates. AgomAb has not generated product revenue to date and reported a net loss of €46.4 million for the year ended December 31, 2024. The offering is led by underwriters J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen.